期刊文献+

老年痴呆患者载脂蛋白E增强子基因多态性分析 被引量:4

Association Analysis of Apolipoprotein E Intron I Enhancer(ApoE IE1) Gene Polymorphisms with Alzheimer,disease or Serum Lipid Level
下载PDF
导出
摘要 目的探讨载脂蛋白(ApoE)基因内含子Ⅰ内的增强子元件(IE1)中存在+133G/C多态性与老年痴呆症(alzheimer’s disease,AD)、血脂代谢紊乱三者之间的相关性,了解贵阳市老年痴呆分子流行病学特征。方法采用多级随机整群抽样方法,用简易智能状态量表对调查对象(共调查3 590人)进行认知功能检查,对筛查确诊为AD的患者采用多聚酶链反应限制性片断长度多态性(PCR-RFLP)技术分析其ApoE IE1的基因型并进行血脂水平检测。结果AD患者组和对照组ApoEIE1基因型分布均符合Hardy-Weinterg平衡,AD组G/G基因型频率显著高于对照组,其血清总胆固醇(TC)水平明显高于正常对照组。结论AD患者ApoE IE1G等位基因频率显著高于对照组,IE1两种等位形式可能影响增强子活性,且与血脂代谢紊乱相伴随。 Objective To investigate the association of the polymorphisms of apolipoprotein E(ApoE) intron 1 enhancer(IE1) with Alzheimer,disease(AD) and serum lipid level.A lot of factors play important roles in occur of AD,but the relationship among these factors and how did they influence each other were not very clear and need further study. Methods The G/C base exchange in the enhancer region +133(ApoE IE1+133 G/C) were determined by polymerase chain reaction restriction fragment length polymorphism(PCR-RFLP) method.On the other hand Total cholesterol(TC) was detected in serum with routine biochemical methods in 40 AD patients as well as 40 control subjects. Results The genotypes of ApoE IE1 were according to Hardy-Weinberg principle.The allele frequencies in the +133 site of ApoE IE1 were 78.75% for the G allele and 58.75% for the C allele.In AD patients,the highest genotype frequency was found to be G/G at 62.5%(n=25) followed by G/C at 32.5%(n=13),C/C 5.0%(n=2).In control subjects G/G at 27.5%(n=11).G/C was 62.5%.C/C is 10%.Obviously the frequency of G/G genotype in AD patients was significantly higher than control group(p<0.05).Moreover detected the level of TC,TG in serum significantly different,the level in G/G with AD was higher than that in control group(P<0.05). Conclusion ApoE IE1 gene polymorphism is closely related to serum lipid,and G/G genotype may be a risk factor of AD.
出处 《贵州医药》 CAS 2012年第5期407-409,共3页 Guizhou Medical Journal
关键词 APOE基因多态性 ApoE内含子1增强子元件 老年痴呆症 分子流行病学 Polymorphism of apolipoprotein E(ApoE) Apolipoprotein E Intron I Enhancer(ApoE IE1) Alzheimer,disease Molecular epidemiology
  • 相关文献

参考文献7

  • 1汤哲,孟琛,陈彪.北京地区老年痴呆流行病学研究[J].中华流行病学杂志,2003,24(8):734-736. 被引量:68
  • 2Farrer LA,Cupples LA,Haines JL. Effects of age,sex,and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease.A metaanalysis ApoE and Alzheimer disease meta analysis consortium[J].Journal of the American Medical Association,1997,(16):1349-1356.
  • 3陈培利.载脂蛋白E基因调控的研究进展[J].中国动脉硬化杂志,1997,5(3):276-279. 被引量:1
  • 4Mui S,Briggs M,Chung H. A newly identified polymorphism in the apolipoprotein E enhancer gene region is association with Alzheimer disease and strongly with the epsilon 4 allele[J].Neurology,1996,(01):196-201.
  • 5王荫华.阿尔茨海默病的危险因素[J].中华神经科杂志,2003,36(6):477-479. 被引量:14
  • 6Paik Y-K,Chang DJ,Reardon CA. Nucleotide sequence and structure of the human Apolipoprotein E gene[J].Proceedings of the National Academy of Sciences(USA),1995,(03):445-447.
  • 7Selkoe DJ. Alzheimer disease:Genotypes,phenotype and treatments[J].Science,1997.275-276.

二级参考文献14

共引文献80

同被引文献40

  • 1Jaturapatporn D, Isaac MG, McCleery J, et al. Aspirin, steroidal and non- steroidalanti. Inflammaory drugs for the treatment of Alzheimer' s disease [J]. Cochrane Data-base Syst Rev, 2012, (2) : CD006378.
  • 2Vellas B, Black R, Thai LJ, et al. AN1792 (QS0-21)-251 Study Team. Long-term Follow-up of patients immunized with AN1792 : reduced functional decline in antibody responders [J]. Curt Alzheimer Res, 2009,6(2) : 144-151.
  • 3Orgogozo JM, Gilman S, Dartigues JF, et al. Subaeute meningoencephalitis in a subset of patients with AD after A(beta) 42 immunization [J]. Neurology, 2008, 61 (1) :46-54.
  • 4Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunization in Alzheimer' s disease: follow-up of a randomised,placebo- controlled phase I trial [J]. Lancet, 2009,372(9634) : 216-223.
  • 5Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease [J]. Neurology, 2009,73(24) :2061-2070.
  • 6Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer' s disease treated with bapineuzumab : a retrospective analysis [J]. Lancet Neurol, 2012,11(3) :241-249.
  • 7Salloway S, Sperling R, Honig L, et al. A randomized, double-blind, placebo- controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer' s disease who are apolipoprotein E e4 non-carriers (presented at the 16th congress of the European Federation of Neurological Societies, Stockholm, Sweden, September 11, 2012) [J]. Eur J Neurol, 2012,19(Suppl 1 ) : 70.
  • 8Spcrling R, Salloway S, Raskind M, et al. A randomized, double-blind, placebo- controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer' s disease who are apolipoprotein E e4 carriers (presented at the 16th Congress of the European Federation of Neurological Societies, Stockholm. Sweden, September 11, 2012) [J]. Eur J Neurol, 2012,19 (Suppl 1 ) : 70.
  • 9Farlow M, Arnold SE, Van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease [J]. Alzheimers Dement, 2012, 8(4) :261-271.
  • 10Doody RS, Thomas RG, Farlow M, et al. Phase 3 studies of solanezumab for mild to moderate Alzheimer' s disease [J]. N Engl J Med, 2014,370(4): 311-321.

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部